Allogene Therapeutics, Inc. has disclosed a notable stock transaction involving its Chief Financial Officer, Geoffrey M. Parker. This transaction, reported in a recent SEC filing, involved the sale of shares to meet tax withholding obligations associated with the vesting of restricted stock units. The move underscores the company's ongoing efforts to manage its employee equity incentives effectively.
Allogene Therapeutics, Inc. operates within the biological products sector, specifically categorized under SIC 2836, which focuses on biological products excluding diagnostic substances. The company trades under the ticker symbol ALLO on the Nasdaq exchange. As a smaller reporting company, Allogene is actively navigating the complexities of the biotech landscape through strategic management of its equity compensation plans.
According to the SEC filing dated October 23, 2026, Parker sold 36,342 shares of common stock on October 21, 2026, at a price of $1.34 per share. This transaction was executed to cover tax obligations arising from the vesting of restricted stock units, a common practice in the industry. The filing noted that this sale does not represent a discretionary trade but is a mandated action under the company's equity incentive plan.
Following this transaction, Parker holds a total of 1,045,877 shares of Allogene's common stock. The filing also indicated that Parker forfeited 195,000 shares subject to performance-based restricted stock units granted on October 10, 2023. Furthermore, it included shares acquired through an employee stock purchase program earlier in 2026.
This transaction may have implications for Allogene's employees and stakeholders, as it reflects the company's approach to equity compensation and tax management. In an industry where talent retention is crucial, effective management of equity incentives can play a significant role in attracting and retaining skilled professionals.
Looking ahead, the filing does not specify what actions will follow this transaction. However, it is clear that Allogene Therapeutics is committed to maintaining a transparent approach to its equity management practices.